Jean‐Philippe Lanoix
Centre Hospitalier Universitaire Amiens-Picardie(FR)Agents infectieux, résistance et chimiothérapie(FR)Université de Picardie Jules Verne(FR)
Publications by Year
Research Areas
COVID-19 Clinical Research Studies, Tuberculosis Research and Epidemiology, Mycobacterium research and diagnosis, SARS-CoV-2 and COVID-19 Research, Long-Term Effects of COVID-19
Most-Cited Works
- → Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial(2021)340 cited
- → Heterogeneous disease progression and treatment response in a C3HeB/FeJ mouse model of tuberculosis(2015)135 cited
- → An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19(2021)106 cited
- → Mutations in fbiD ( Rv2983 ) as a Novel Determinant of Resistance to Pretomanid and Delamanid in Mycobacterium tuberculosis(2020)86 cited
- → Characteristics and outcomes ofCOVID‐19 in hospitalized patients with and without diabetes(2020)86 cited
- → Dynamic profile for the detection of anti-SARS-CoV-2 antibodies using four immunochromatographic assays